SCHEDULE 13G: BlackRock Discloses 6.4% Stake in Nuvation Bio Inc.

BlackRock, Inc. has filed a Schedule 13G, reporting a beneficial ownership of 6.4% in Nuvation Bio Inc.'s common stock as of June 30, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 21,708,843 shares of Nuvation Bio Inc. common stock.
• This aggregate amount represents 6.4% of Nuvation Bio Inc.'s common stock class.
• BlackRock holds sole voting power over 21,153,392 shares and sole dispositive power over 21,708,843 shares.
• The filing was made under Rule 13d-1(b), indicating that BlackRock is a passive investor and not seeking to influence control of the issuer.
• The shares were acquired and are held in the ordinary course of business.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of ownership, providing neutral information without positive or negative performance implications for the issuer.

Positives

• BlackRock, a major institutional investor, holding a significant stake (6.4%) in Nuvation Bio Inc. may signal confidence in the company's long-term prospects.
• The filing indicates a passive investment, suggesting BlackRock is not pursuing an activist role that could create instability.

Risks

• The concentration of a significant portion of shares (6.4%) in a single institutional holder like BlackRock could lead to increased volatility if BlackRock decides to significantly alter its position.
• While stated as a passive investment, large institutional holdings can still exert indirect influence on corporate decisions.

Future Outlook

The document is an ownership disclosure and does not contain any forward-looking statements or guidance regarding Nuvation Bio Inc.'s future performance or strategic direction.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing represents a routine disclosure of significant passive institutional ownership in a publicly traded biotechnology company. Such disclosures are common and provide transparency regarding major shareholders in the market.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder, which can influence market perception and trading activity.
• Management: Awareness of a large passive investor, though without direct control implications.

Key Dates

Keywords

Nuvation Bio Inc., BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing, Biotechnology, Healthcare